# Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke

Study · id `cardio:ct-nct07365475` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07365475](<https://clinicaltrials.gov/study/NCT07365475>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07365475

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 306 participants.

## Technical summary

Registry record NCT07365475. Randomized; single masking; primary purpose treatment. Start 2026-01-30 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 306 participants (planned count; ClinicalTrials.gov record NCT07365475, source copy `cardio:ctgov-nct07365475-2026-01-26`, retrieved 2026-10-26)
- Planned start: 2026-01-30 (anticipated) (ClinicalTrials.gov record NCT07365475, source copy `cardio:ctgov-nct07365475-2026-01-26`, retrieved 2026-10-26)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07365475, source copy `cardio:ctgov-nct07365475-2026-01-26`, retrieved 2026-10-26)
- Completion: 2028-08-30 (anticipated) (ClinicalTrials.gov record NCT07365475, source copy `cardio:ctgov-nct07365475-2026-01-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07365475-2026-01-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke
- Acronym: AMASS2
- Condition: Acute Ischemic Stroke From Large Vessel Occlusion
- Intervention (Drug): 20% human serum albumin
- Lead sponsor: Tianjin Huanhu Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Tianjin Huanhu Hospital (`cardio:org-tianjin-huanhu-hospital`)

## Provenance

Content hash: c16300930d8cb5517ac6ba0c433553d2f55f775e13a04dbae5710885f60d15ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
